Detalhe da pesquisa
1.
Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6.
Blood
; 121(22): 4493-503, 2013 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-23603913
2.
NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
Int J Cancer
; 132(6): 1360-7, 2013 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22907642
3.
PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.
Int J Cancer
; 130(10): 2327-36, 2012 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21717461
4.
Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
Int J Cancer
; 125(3): 649-55, 2009 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19444908
5.
A high-throughput RNAi screen for detection of immune-checkpoint molecules that mediate tumor resistance to cytotoxic T lymphocytes.
EMBO Mol Med
; 7(4): 450-63, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25691366
6.
Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C.
J Hypertens
; 20(5): 885-93, 2002 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12011649
7.
HLA Class II tetramers reveal tissue-specific regulatory T cells that suppress T-cell responses in breast carcinoma patients.
Oncoimmunology
; 2(6): e24962, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23894725
8.
Targeting the epidermal growth factor receptor (HER) family by T cell receptor gene-modified T lymphocytes.
J Mol Med (Berl)
; 88(11): 1113-21, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20700725
9.
Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein.
Virology
; 395(1): 45-55, 2009 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-19800648
10.
CTLs directed against HER2 specifically cross-react with HER3 and HER4.
J Immunol
; 180(12): 8135-45, 2008 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18523278
11.
Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer.
Cancer Immunol Immunother
; 57(2): 271-80, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17646988